An investing piece arguing that Lilly's drug discovery pipeline, not Zepbound, is the company's real strength for future growth.
Recap by typeshit. Full story at The Motley Fool on MSN.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Penn State Science says the new funding supports work that uses AI to identify synthetic peptides with potential for drug development.
Exercise advice aimed at people on GLP-1 medication, shared without further detail on the specific workouts recommended.
Loading…